CAS: 38242-02-3; (4Ar,6As,6Br,8Ar,10S,12As,12Br,14Br)-10-Hydroxy-2,2,4A,6A,6B,9,9,12A-Octamethyl-1,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,12B,14B-Octadecahydropicen-13(2H)-One

该化合物是一种来自自然来源的三元素化合物,因其在制药和生化研究中的潜在应用而得到承认,其结构的特点是带有氯酮功能组的β-氨基质骨骼,有助于其在合成途径中的回作用和实用性.该化合物因其已表现出生物活动,包括抗炎和抗微生物特性,因而值得注意,因此它成为进一步进行药理研究的候选体.β-阿米诺诺醇的稳定性和纯度对于可复制的实验结果至关重要,而且通常被用作分析化学的参考标准.其定义明确的分子特性有助于调查三元素研究的结构-活动关系.

结构式图片

上下游产品

3β-hydroxyolean-12-en-11-one acetate 3β-benzoyloxy-oleanen-(12)-one-(11) benzene beta-amyrin3β-hydroxy-olean-9(11),12-diene 3β-hydroxyolean-12-en-11-one acetate 3β-benzoyloxy-oleana-9(11),12-diene

合成工艺路线路线简述

    📜3β-Hydroxyolean-12-En-11-One Acetate置于氢氧化钾体系中,化学反应生成 Beta-香树脂酮醇
    参考文献:Long-Term Glycemic Control Measurements In Diabetic Patients Receiving Hemodialysis
    标题:Long-Term Glycemic Control Measurements In Diabetic Patients Receiving Hemodialysis
    摘要:Cardiovascular Morbidity Is Increased In Patients With Diabetes Mellitus And There Is A Great Prevalence Of Diabetes And Cardiovascular Disease Among Patients With End-Stage Renal Disease (Esrd). Control Of Glycemia Can Decrease Cardiovascular And End-Organ Damage. Because The Validity Of Glycemic Control Tests Have Not Been Rigorously Studied In Patients With Esrd,We Evaluated The Value Of Various Measures In These Patients. The Overall Clinical Goal Was To Investigate Whether Hemoglobin A(1)C (A(1)C) Accurately Reflects Actual Glycemic Control As Compared With Other Measures In Light Of The Importance Of Attaining Appropriately Controlled Blood Glucose (Bg). The Commonly Used Tests Of Total Glycated Hemoglobin (Ghb) And A(1)C May Be Unreliable In Patients With Esrd Because Of The Presence Of Anemia,Shortened Red Blood Cell (Rbc) Survival,And Assay Interferences From Uremia. The Primary Aim Of This Study Was To Assess The Relationship Of Capillary Bg Measurements To A(1)C,Ghb,Total Glycated Plasma Proteins (Gpp),And Fructosamine (Fr) In Diabetic Patients Receiving Hemodialysis. Twenty-Three Patients Were Instructed To Obtain Bg Evaluations Twice Daily For 7 Days By Using The Elite Glucometer (Bayer Corporation,Elkhart,In). These Determinations Included 6 Fasting,6 Preprandial,And 3 Separate 2-Hour Postprandial Levels. Blood Was Obtained On Day 7 For Measurement Of A(1)C,Ghb,Gpp,And Fr. A(1)C Was Analyzed By An Immunoassay,Gpp And Ghb Were Assayed By Affinity High-Performance Liquid Chromatography (HPLC),And Fr By Automated Nitroblue Colorimetric Assay. Scatter Plots Were Generated By Plotting The Average Bg Versus A(1)C,Ghb,Gpp,Or Fr. Linear Regression Was Performed For Each Plot Showing The Following Relationships: A(1)C = 0.0174 (Bg) + 4.76 (R = 0.58; P < 0.05): Ghb = 0.0371 (Bg) + 3.57 (R = 0.584; P < 0.05): Gpp = 0.0083 (Bg) + 26.13 (R = 0.065; P = 0.77): Fr = 0.6865 (Bg) + 250 (R = 0.345; P = 0.11). Despite Anemia And Shortened Rbc Lifespan In Patients With Esrd,A(1)C In The Range Of 6% To 7% Estimates Glycemic Control Similarly To Patients Without Severe Renal Impairment. A(1)C Values Above 7.5% May Overestimate Hyperglycemia In Patients With Esrd. Thus,Diabetic Patients Receiving Hemodialysis May Have Long-Term Bg That Are More Properly Controlled Than Previously Determined,Reducing Their Risks Of The Macro-And Microvascular Complications Of Diabetes Mellitus. (C) 2002 By The National Kidney Foundation,Inc.
    DOI:10.1053/ajkd.2002.30549

    海关参考信息

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献

    合成方法参考DOI号:10.1053/ajkd.2002.30549
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知